We selected PTK7 as the target due to its high expression in both primary and metastatic tumors, which is strongly associated with tumor progression, metastasis and poor prognosis.[24] To target PTK7, we designed a scFv(PTK7) derived from Cofetuzumab Pelidotin (Cofe‐P),[25] a PTK7‐targeting antibody‐drug conjugate (Figure 2a). This evidence concerns the gene PTK7 and neoplasm.